


PATENT



Attorney Docket No. NUCL-006/01US
Application No. 10/560,377
(US Nat'l. Stage of PCT/US04/19229)
Page 1

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Catherine J. PACHUK *et al.* Confirmation No.: 3823

Application No.: 10/560,377

Group Art Unit: *To Be Assigned*

Int'l. Filing Date: June 10, 2004

Examiner: *To Be Assigned*

For: Conserved HBV and HCV Sequences Useful for Gene Silencing

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

1

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,
Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97
and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, copies of documents 1-3 cited in the attached Form PTO-1449 are enclosed.
- ☐ Copies of the remaining publications listed on the attached Form PTO-1449 are not being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial Nos.:
to which the above-identified application claims priority under 35 U.S.C. §120.
- ☐ Copies of documents that were not submitted in the above-mentioned related United States Patent Applications may be found in related United States Patent Application Nos.:
Should the Examiner be unable to locate a document, a copy will be provided upon request.
- ☐ No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO-1449 are being provided pursuant to 37 C.F.R. §1.98.

- [] Document ____ is the PCT Patent publications of Applicants' related PCT Application no. _____, filed _____.
- [x] Documents 1 and 2 were cited in a Search Report mailed September 16, 2005 (cited herein as document 3), in Applicants' related PCT patent application no. PCT/US2004/019229, filed June 10, 2004.
- [x] Document 3 is an official communications from a foreign patent office received in Applicants' related PCT Application no. PCT/US2004/019229, filed June 10, 2004.
- [] Documents _____ submitted herewith were not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.
- [] Enclosed is a copy of a non-English publication(s) _____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- [] Enclosed is a copy of a non-English publication(s) _____. English language publication ____ (copy enclosed) claims priority from this non-English publication.
- [] Enclosed are abstracts of non-English publications _____, cited herein as documents _____ respectively. English abstracts are attached to each document. An English abstract of non-English publication _____, document _____, may be found on the cover page of the publication.
- [] Enclosed is an English translation of non-English publications _____, cited herein as documents _____ respectively. English translations are attached to each document.
- [] The Examiner's attention is directed to related co-pending United States Patent Application Serial Nos.:

PATENT

Attorney Docket No. NUCL-006/01US
Application No. 10/560,377
(US Nat'l. Stage of PCT/US04/19229
Page 3

_____, filed _____, cited herewith as _____; and
_____, filed _____, cited herewith as _____.

This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.


It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO-1449 to the undersigned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-1283.


Dated: March 21, 2007

USPTO Customer No. 58249
COOLEY GODWARD KRONISH LLP
ATTN: Patent Group
The Bowen Building
875 15th Street, NW Suite 800
Washington, DC 20005-2221
Phone: (202) 842-7800
Fax: (202) 842-7899

Respectfully submitted,
COOLEY GODWARD KRONISH LLP

By:


Bonnie Weiss McLeod
Reg. No. 43,255

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)  PTO Form 1449				Attorney Docket No. NUCL-006/01US		Application No. 10/560,377 (US Nat'l. Stage of PCT/US04/19229)			
				Applicants: Catherine J. PACHUK <i>et al.</i>				PAGE 1 of 1	
				Int'l. Filing Date: June 10, 2004		Group Art Unit: <i>To Be Assigned</i>			
U.S. PATENT DOCUMENTS									
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date		
FOREIGN PATENT DOCUMENTS									
		Document No.	Date	Country	Class	Sub-Class	Translation		
/B.P./	1.	WO 03/070918 A2	08/28/2003	WIPO					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)									
/B.P./	2.	Holen et al., "Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway," Nucl. Acids Res. 31:2401-2407 (2003).							
/B.P./	3.	Macchia, "International Search Report," from PCT/US2004/019229, filed June 10, 2004, 8 pages, European Patent Office, Rijswijk, The Netherlands (mailed September 16, 2005).							
Examiner		/Bo Peng/		Date Considered		06/18/2009			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

PATENT

IFW
Attorney Docket No. NUCL-006/01US
Application No. 10/560,377
(US Nat'l. Stage of PCT/US04/19229
Page 1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Catherine J. PACHUK *et al.* Confirmation No.: 3823

Application No.: 10/560,377

Group Art Unit: *To Be Assigned*

Int'l. Filing Date: June 10, 2004

Examiner: *To Be Assigned*

For: Conserved HBV and HCV Sequences Useful for Gene Silencing

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,
Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97
and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, copies of documents 2-13 cited in the attached Form PTO-1449 are enclosed.
- ☐ Copies of the remaining publications listed on the attached Form PTO-1449 are not being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial Nos.:
to which the above-identified application claims priority under 35 U.S.C. §120.
- ☐ Copies of documents that were not submitted in the above-mentioned related United States Patent Applications may be found in related United States Patent Application Nos.:
Should the Examiner be unable to locate a document, a copy will be provided upon request.
- ☒ No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO-1449 are being provided pursuant to 37 C.F.R. §1.98.

- ☒ Document 2 is the PCT Patent publications of Applicants' related PCT Application no. PCT/US04/19229, filed June 10, 2004.
- ☒ Documents 1 and 5-13 were cited in a Search Report mailed October 12, 2006 (cited herein as document 4), in Applicants' related SG Application no. 200507781-3.
- ☒ Documents 3 and 4 are official communications from foreign patent offices received in Applicants' related SG Application no. 200507781-3.
- ☐ Documents _____ submitted herewith were not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.
- ☐ Enclosed is a copy of a non-English publication(s) _____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- ☐ Enclosed is a copy of a non-English publication(s) _____. English language publication ____ (copy enclosed) claims priority from this non-English publication.
- ☐ Enclosed are abstracts of non-English publications _____, cited herein as documents _____ respectively. English abstracts are attached to each document. An English abstract of non-English publication _____, document _____, may be found on the cover page of the publication.
- ☐ Enclosed is an English translation of non-English publications _____, cited herein as documents _____ respectively. English translations are attached to each document.
- ☐ The Examiner's attention is directed to related co-pending United States Patent Application Serial Nos.:
_____, filed _____, cited herewith as _____; and

PATENT

Attorney Docket No. NUCL-006/01US
Application No. 10/560,377
(US Nat'l. Stage of PCT/US04/19229
Page 3

_____, filed _____, cited herewith as _____.

This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Forms PTO-1449 to the undersigned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-1283.

Dated: Dec. 26, 2006

USPTO Customer No. 58249
COOLEY GODWARD KRONISH LLP
ATTN: Patent Group
The Bowen Building
875 15th Street, NW Suite 800
Washington, DC 20005-2221
Phone: (202) 842-7800
Fax: (202) 842-7899

Respectfully submitted,
COOLEY GODWARD KRONISH LLP

By:

Bonnie Weiss McLeod
Bonnie Weiss McLeod
Reg. No. 43,255

INFORMATION DISCLOSURE CITATION

Attorney Docket No.
NUCL-006/01US

Application No.
10/560,377 (US Nat'l. Stage of
PCT/US04/19229)

(Use several sheets if necessary)

Applicants: Catherine J. PACHUK *et al.*

PAGE 1 of 1

PTO Form 1449

Int'l. Filing Date: June 10, 2004

Group Art Unit: *To Be Assigned*

U.S. PATENT DOCUMENTS

Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
/B.P./	1.	6,518,417	02/11/2003	Sczakiel <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Sub-Class	Translation
/B.P./	2.	WO 2005/014806	02/17/2005	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

/B.P./	3.	Mackenzie, "Written Opinion," from SG 200507781-3, filed June 10, 2004, 6 pages, Australian Patent Office (mailed October 12, 2006).					
	4.	Mackenzie, "Search Report," from SG 200507781-3, filed June 10, 2004, 7 pages, Australian Patent Office (mailed October 12, 2006).					
	5.	Andino, "RNAi puts a lid on virus replication," <i>Nat. Biotechnol</i> 21(6):629-630 (2003).					
	6.	Couzin, "Mini RNA Molecules Shield Mouse Liver From Hepatitis," <i>Science</i> 299:995 (2003).					
	7.	Hamasaki <i>et al.</i> , "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> 543:-51-54 (2003).					
	8.	Kapadia <i>et al.</i> , "Interference of hepatitis C virus RNA replication by short interfering RNAs," <i>Proc. Natl. Acad. Sci. USA</i> 100(4):2014-2018 (2003).					
	9.	McCaffrey <i>et al.</i> , "RNA interference in adult mice," <i>Nature</i> 418:38-39 (2002).					
	10.	McCaffrey <i>et al.</i> , "Inhibition of hepatitis B virus in mice by RNA interference," <i>Nat. Biotechnol.</i> 21(6):639-644 (2003).					
	11.	Seo <i>et al.</i> , "Small Interfering RNA-Mediated Inhibition of Hepatitis C Virus Replication in the Human Hepatoma Cell Line Huh-7," <i>J. Virol.</i> 77(1):810-812 (2003).					
	12.	Shlomai and Shaul, "Inhibition of Hepatitis B Virus Expression and Replication by RNA Interference," <i>Hepatology</i> 37:764-770 (2003).					
↓	13.	Wilson <i>et al.</i> , "RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells," <i>Proc. Natl. Acad. Sci. USA</i> 100(5):2783-2788 (2003).					

Examiner

/Bo Peng/

Date Considered

06/18/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>	
		Application Number	10/560,377
		Filing Date	June 19, 2006
		First Named Inventor	Catherine J. Pachuk et al.
		Group Art Unit	
Examiner Name			
Sheet	1 of 1	Attorney Docket Number	NUCL-006/01US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
/B.P./	B1	WO 04/078181 (A1)	09-16-2004	CAPITAL BIOCHIP COMPANY, LTD. & TSINGHUA UNIVERSITY		

OTHER – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/B.P./	C1	European Search Report based on European Patent Application No. 04776661.3, (January 14, 2008).			

Examiner Signature	/Bo Peng/	Date Considered	06/18/2009
-----------------------	-----------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number (optional). ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT



Attorney Docket No. NUCL-006/01US
Application No. 10/560,377
Page 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Catherine J. PACHUK *et al.* Confirmation No.: 3823

Application No.: 10/560,377

Group Art Unit: *To Be Assigned*

Int'l. Filing Date: June 10, 2004

Examiner: *To Be Assigned*

For: Conserved HBV and HCV Sequences Useful for Gene Silencing

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,

Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, copies of documents 1-3 cited in the attached Form PTO-1449 are enclosed.
- ☐ Copies of the remaining publications listed on the attached Form PTO-1449 are not being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial Nos.:
to which the above-identified application claims priority under 35 U.S.C. §120.
- ☐ Copies of documents that were not submitted in the above-mentioned related United States Patent Applications may be found in related United States Patent Application Nos.:
Should the Examiner be unable to locate a document, a copy will be provided upon request.
- ☐ No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO-1449 are being provided pursuant to 37 C.F.R. §1.98.

- ☐ Document __ is the PCT Patent publications of Applicants' related PCT Application no. _____, filed _____.
- ☒ Documents 2 and 3 were cited in an International Preliminary Report On Patentability mailed January 31, 2007 (cited herein as document 1), in Applicants' related PCT Application no. PCT/US04/19229.
- ☒ Document 1 is an official communication from a foreign patent office received in Applicants' related PCT Application no. PCT/US04/19229.
- ☐ Documents _____ submitted herewith were not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.
- ☐ Enclosed is a copy of a non-English publication(s) _____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- ☐ Enclosed is a copy of a non-English publication(s) _____. English language publication ____ (copy enclosed) claims priority from this non-English publication.
- ☐ Enclosed are abstracts of non-English publications _____, cited herein as documents _____ respectively. English abstracts are attached to each document. An English abstract of non-English publication _____, document _____, may be found on the cover page of the publication.
- ☐ Enclosed is an English translation of non-English publications _____, cited herein as documents _____ respectively. English translations are attached to each document.
- ☐ The Examiner's attention is directed to related co-pending United States Patent Application Serial Nos.:
_____, filed _____, cited herewith as _____; and
_____, filed _____, cited herewith as _____.

PATENT



Attorney Docket No. NUCL-006/01US
Application No. 10/560,377
Page 3

This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Forms PTO-1449 to the undersigned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-1283.

Dated: Feb. 27, 2007

USPTO Customer No. 58249
COOLEY GODWARD KRONISH LLP
ATTN: Patent Group
The Bowen Building
875 15th Street, NW Suite 800
Washington, DC 20005-2221
Phone: (202) 842-7800
Fax: (202) 842-7899

Respectfully submitted,
COOLEY GODWARD KRONISH LLP

By:

Bonnie Weiss McLeod
Bonnie Weiss McLeod
Reg. No. 43,255

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Attorney Docket No. NUCL-006/01US		Application No. 10/560,377			
		Applicants: Catherine J. PACHUK <i>et al.</i>		PAGE 1 of 1			
PTO Form 1449		Int'l. Filing Date: June 10, 2004		Group Art Unit: <i>To Be Assigned</i>			
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
/B.P./	1.	Ford, "International Preliminary Report On Patentability," from PCT/US04/19229, filed June 10, 2004, 5 pages, United States Patent and Trademark Office, IPEA/US, (mailed January 31, 2007).					
/B.P./	2.	Giladi <i>et al.</i> , "Small Interfering RNA Inhibits Hepatitis B Virus Replication in Mice," <i>Mol. Ther.</i> 8(5):769-776 (2003).					
/B.P./	3.	Randall <i>et al.</i> , "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs," <i>Proc. Natl. Acad. Sci. USA</i> 100(1):235-240 (2003).					
Examiner		/Bo Peng/		Date Considered		06/18/2009	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							